Dr. Martha Hernandez-Illas

Rheumatology
5333 N Dixie Hwy, Suite 110, 
Fort Lauderdale, FL 
5333 N Dixie Hwy, Suite 110, 
Fort Lauderdale, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Martha Hernandez-Illas is a Rheumatologist in Fort Lauderdale, Florida. Her top areas of expertise are Gout and Arthritis.

Her clinical research consists of co-authoring 14 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D

Locations

5333 N Dixie Hwy, Suite 110, Fort Lauderdale, FL 33334

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 1, Open-Label, Randomized Study to Evaluate Safety and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin (Human) Investigational Product (COVID-HIG) Administered Through Intramuscular, Subcutaneous or Intravenous Routes as a Single Dose Regimen to SARS-CoV-2 Uninfected Adults
A Phase 1, Open-Label, Randomized Study to Evaluate Safety and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin (Human) Investigational Product (COVID-HIG) Administered Through Intramuscular, Subcutaneous or Intravenous Routes as a Single Dose Regimen to SARS-CoV-2 Uninfected Adults
Enrollment Status: Completed
Publish Date: June 08, 2025
Intervention Type: Biological
Study Phase: Phase 1
Evaluation of the Pharmacokinetics and Safety of NT-814 in Post-Menopausal Women With Vasomotor Symptoms
Evaluation of the Pharmacokinetics and Safety of NT-814 in Post-Menopausal Women With Vasomotor Symptoms
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Subcutaneous Doses of LY3493269 in Patients With Type 2 Diabetes Mellitus
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Subcutaneous Doses of LY3493269 in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176 and Multiple Doses in Patients With Type 2 Diabetes Mellitus
A Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176 and Multiple Doses in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: January 16, 2024
Intervention Type: Drug
Study Phase: Phase 1
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 Alone and in Combination With GLP-1 RA in Patients With Type 2 Diabetes
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 Alone and in Combination With GLP-1 RA in Patients With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: January 11, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3819469
A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3819469
Enrollment Status: Completed
Publish Date: November 21, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Multiple Dose Study in Healthy Overweight and Obese Participants to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3502970
A Multiple Dose Study in Healthy Overweight and Obese Participants to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3502970
Enrollment Status: Completed
Publish Date: October 18, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Single-Ascending and Repeat-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3561774
A Single-Ascending and Repeat-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3561774
Enrollment Status: Completed
Publish Date: August 10, 2022
Intervention Type: Drug
Study Phase: Phase 1
Bioequivalence of an Alternate Ixekizumab Formulation Compared to the Commercial Formulation in Healthy Subjects
Bioequivalence of an Alternate Ixekizumab Formulation Compared to the Commercial Formulation in Healthy Subjects
Enrollment Status: Completed
Publish Date: April 08, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Patients With Type 2 Diabetes Mellitus
A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: January 20, 2021
Intervention Type: Drug
Study Phase: Phase 1
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3209590 Following Multiple Weekly Doses in Patients With Type 2 Diabetes Mellitus
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3209590 Following Multiple Weekly Doses in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: December 11, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

14 Total Publications

Combined GPR40 and GPR119 full agonism with K-757 and K-833 results in robust glucose lowering and modest weight loss in overweight/obese subjects with T2DM.
Combined GPR40 and GPR119 full agonism with K-757 and K-833 results in robust glucose lowering and modest weight loss in overweight/obese subjects with T2DM.
Journal: Diabetes, obesity & metabolism
Published: June 13, 2025
Similar Doctors
Expertise in
19
conditions
Dr. Shawn B. Baca
Rheumatology
Expertise in
19
conditions
Dr. Shawn B. Baca
Rheumatology

Rheumatology Associates Of South Florida

1050 NW 15th Street, Suite 212A, 
Boca Raton, FL 
 (11.8 miles away)
561-368-5611
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Shawn Baca is a Rheumatologist in Boca Raton, Florida. Dr. Baca is highly rated in 19 conditions, according to our data. His top areas of expertise are Postmenopausal Osteoporosis, Osteoporosis, Melorheostosis, and Melorheostosis with Osteopoikilosis. Dr. Baca is currently accepting new patients.

Expertise in
13
conditions
Dr. Richard S. Glick
Rheumatology
Expertise in
13
conditions
Dr. Richard S. Glick
Rheumatology
6405 N Federal Hwy, Suite 105, 
Fort Lauderdale, FL 
 (1.7 miles away)
954-772-3660
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Richard Glick is a Rheumatologist in Fort Lauderdale, Florida. Dr. Glick is highly rated in 13 conditions, according to our data. His top areas of expertise are Mixed Connective Tissue Disease, MASS Phenotype, Necrotizing Vasculitis, and Rheumatoid Arthritis (RA). Dr. Glick is currently accepting new patients.

Expertise in
22
conditions
Dr. Steven C. Kimmel
Rheumatology
Expertise in
22
conditions
Dr. Steven C. Kimmel
Rheumatology

American Arthritis And Rheumatology Associates LLC

7431 N University Dr, Suite 300, 
Tamarac, FL 
 (7.7 miles away)
954-724-5560
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Kimmel is a Rheumatologist in Tamarac, Florida. Dr. Kimmel is highly rated in 22 conditions, according to our data. His top areas of expertise are Psoriatic Arthritis, Psoriasis, Rheumatoid Arthritis (RA), and Undifferentiated Connective Tissue Disease (UCTD). Dr. Kimmel is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hernandez-Illas's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile